Industry Knowledge¶
Market Overview¶
| Metric | Value |
|---|---|
| Veterinary diagnostics market (2023) | ~$4.5 B |
| Projected (2030) | ~$8.5 B |
| CAGR | ~9–10% |
| POCT segment | ~30% (fastest-growing) |
Technology Roadmap¶
| Stage | Technology |
|---|---|
| Past | Qualitative colloidal-gold LFIA |
| Present | Quantitative FICT (instrument-read) |
| Future | Cloud-connected, multi-analyte POCT |
Regulatory Landscape¶
| Region | Framework |
|---|---|
| EU | IVDR (2017/746) — CE marking |
| US | FDA veterinary device regulations |
| China | NMPA IVD registration |
Explore This Domain¶
- Veterinary POCT Market — market size and growth drivers
- Technology Roadmap — from qualitative to quantitative POCT
- Regulatory Landscape — IVDR, FDA, NMPA
FAQ¶
Why is POCT growing faster than lab testing? Same-visit results improve compliance and retain testing revenue in-clinic.
What is driving the shift to quantitative POCT? Clinical demand for monitoring (CRP/SAA serial testing, progesterone timing) requires concentration, not just positive/negative.
For market data, see the Data Hub.
Authored by: Migibio Clinical & Scientific Affairs, Guangzhou Magic Biotech Co., Ltd.
Reviewed by: Migibio R&D Quality Committee
Last updated: 2026-08-13
Disclosure: Migibio (Guangzhou Magic Biotech Co., Ltd.) is the manufacturer of the FIA680/FIA880 analyzers and FICT reagents referenced in this content. See our Editorial & Review Policy.
Contact: Martin.Wong · Phone (WhatsApp): +86 13323237275 · Email: martinwang2024@gmail.com